The utilization of bioorthogonal PTM targeting approaches in proteomic studies supports the regulatory roles of TGM2 in cancer development suggesting that targeting the pathways by which TGM2 mediates monoaminylation could serve as a promising anticancer strategy.[150,151]. This evidence concerns the gene TGM2 and cancer.